Introduction/Background Cervical cancer (CaCx) is one of the common malignancies in women worldwide. Autophagy is a significant hallmark of cancer wherein high mobility group box 1 (HMGB-1) plays a crucial role. Aberrant expression of HMGB-1 is associated with tumor development, progression and poor prognosis. There are no reports available studying HMGB-1, autophagy related molecule in context to clinical significance in cancer cervix. Thus, we aim to investigate the association between HMGB-1 and its associated molecules (RAGE, p53 & p62) in CaCx. We have also evaluated the clinical significance of serum HMGB-1 in CaCx diagnosis.

Methodology 50 subjects including 20 CaCx patients, 20 healthy women and 10 controls having gynecological disorder other than malignancy were recruited. Circulatory levels of HMGB-1 were measured by ELISA. mRNA and protein levels of HMGB-1 and its associated molecules were quantitated using Q-PCR and western blotting respectively in tissues of study subjects. The data obtained were then validated using Q-PCR and western blotting respectively in tissues of study subjects. The data obtained were then validated using Q-PCR and western blotting respectively in tissues of study subjects. The data obtained were then validated using Q-PCR and western blotting respectively in tissues of study subjects. The data obtained were then validated using Q-PCR and western blotting respectively in tissues of study subjects. The data obtained were then validated using Q-PCR and western blotting respectively in tissues of study subjects.

Results Circulatory levels of HMGB-1 were significantly higher in patients as compared to controls. mRNA and protein expression of HMGB-1 were significantly higher in tumor tissues. The levels of RAGE, p53 and p62 were also significantly altered than their expression in controls at mRNA and protein levels. ROC curve analysis showed better sensitivity and specificity for HMGB-1 for non-invasive diagnosis of CaCx in liquid biopsy. Furthermore, siRNA-mediated targeting of HMGB-1 significantly altered expression of associated molecules, thus, validating the patients’ data.

Conclusion HMGB-1 level could be a useful marker for evaluating disease and diagnosis in non-invasive liquid biopsy. Autophagy mediated HMGB-1/RAGE pathway might play a significant role in pathogenesis of CaCx. Validation in larger patient cohort might exploit HMGB-1 as a novel non-invasive diagnostic marker for CaCx in liquid biopsy in future.
prognosis, however markers that further risk-stratify intermediate groups are needed. Serum cancer antigen-125 (CA125) and human epididyms-4 (HE4) show promise as prognostic markers. The aim of this study was to evaluate the association between serum CA125, HE4 and endometrial cancer survival outcomes when stratified by molecular subgroup.

**Methodology** Pre-treatment serum CA125 and HE4 levels were measured and endometrial tumours classified according to WHO molecular classification. The relationship between biomarkers and survival was evaluated using Kaplan-Meier analysis and multivariable cox regression.

**Results** Overall, 327 women were included, with POLE status available for 216. Tumours were POLE-mutant (5%), p53-abnormal (11%), MMR-deficient (30%) and NSMP (54%).

Median follow up was 50 months (IQR 30–60), during which 42 (13%) recurred and 71 (21%) women died. CA125≥35U/mL was independently associated with overall mortality [aHR=2.42 (95%CI:1.45–3.50)], cancer specific death [aHR=2.00 (95%CI:1.04–3.87)], p=0.04] and recurrence [aHR=2.69 (95%CI:1.38–5.27), p=0.004]. When stratified by molecular subgroup, CA125≥35U/mL and HE4≥150pmol/L were prognostic of overall survival in MMR-deficient [CA125: aHR=4.92 (95%CI:1.74–13.89), p=0.003 and HE4: aHR=4.03 (95%CI:1.34–12.11), p=0.01] and NSMP subgroups [CA125: aHR=3.72 (95%CI:1.30–10.67), p=0.011].

**Conclusion** CA125 and HE4 may risk-stratify those at intermediate risk of recurrence and death. Evaluation in a larger population is required.

**Introduction/Background** Making an early diagnosis of cancer is the challenge that modern medicine has been setting for several decades. In gynecology, no effective screening has yet been found and approved for endometrial and ovarian cancer, and, despite cervical cytology testing, cervical cancer remains a leading cause of morbidity and mortality among gynecological cancers worldwide. The emerging technique of liquid biopsy has been proposed as a method for detecting cancer in early stage using biofluids and their properties as biomarkers.

**Methodology** In this study, we tested the application of an artificial intelligence (AI) algorithm on infra-red spectra taken from urine samples from 84 female patients with gynecological cancer (28 breast, 32 endometrial, 24 ovarian and 10 cervical) and 200 non-tumor patients who were used as controls. The spectra were normalized, and outlier values were detected and removed using a DBSCAN algorithm. To overcome the possible problem of an unbalanced dataset, we used a SMOTE algorithm enhancing the generalization of the predictive model. The AI-model was trained and tested in classifying healthy urine samples vs different cancer types.

**Introduction/Background** In early cervical cancer (ECC) patients with nodal metastasis (N+) present worse survival. However, 10–15% of patients without nodal metastasis (N0) present the same survival to N+ patients. As in cervical cancer, HPV DNA could be assimilated to tumoral DNA, we evaluate the presence of HPV DNA in pelvic Sentinel lymph nodes (SLN) by new ultrasensitive droplet-based digital polymerase chain reaction (ddPCR) as a biomarker of survival.

**Methodology** Inclusion criteria: ECC patients who underwent pelvic SLN detection N0 in pelvic lymph nodes. Associated pelvic lymph nodes samples were available for 60 patients with HPV16, HPV18 or HPV33 positive tumours. In SLN, after DNA extraction, HPV16 E6, HPV18 E7 and HPV33 E6 gene were respectively targeted and detected by ultrasensitive ddPCR optimized on two different platforms, the RainDrop Digital PCR System (RainDance Technologies, Bio-Rad, Hercules, CA) or the Biorad system. We compare two groups according to HPV DNA in SLN: positive or negative.

**Results** There was no difference between the negative HPV DNA SLN group and the positive HPV DNA SLN group in terms of patients and surgical-pathological characteristics, treatments and time of follow-up. Two patients in negative HPV DNA SLN group and 6 in positive HPV DNA SLN group presented recurrence and the mean time of recurrence was 60 months.